Clear Labs raises $21M Series B2 to expand world’s only automated NGS platform for routine pathogen testing
Currently, Clear Safety supports high-volume testing for Salmonella, with the expectation to add support for additional pathogens and software features in 2019.
Clear Labs, Menlo Park, Calif., close $21 million in funding Series B2 to ramp up commercial operations and build new features for Clear Safety, what is said to be the world’s only automated NGS platform for routine pathogen testing.
The series was led by Menlo Ventures, Menlo Park, Calif., with participation from Wing Venture Capital, Menlo Park, Calif.; Dentsu Ventures, Japan; Felicis Ventures, Menlo Park, Calif.; Khosla Ventures, Menlo Park, Calif., and a number of food production companies.